Armata PharmaceuticalsARMP
ARMP
About: Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Employees: 75
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 23 [Q2] → 23 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.06% less ownership
Funds ownership: 3.88% [Q2] → 3.82% (-0.06%) [Q3]
15% less capital invested
Capital invested by funds: $3.86M [Q2] → $3.28M (-$583K) [Q3]
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
98% less call options, than puts
Call options by funds: $1K | Put options by funds: $45K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
220%
upside
Avg. target
$7
220%
upside
High target
$7
220%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 81 / 283 met price target | 220%upside $7 | Buy Reiterated | 14 Nov 2024 |
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 81 / 283 met price target | 220%upside $7 | Buy Reiterated | 12 Nov 2024 |
Financial journalist opinion
Based on 4 articles about ARMP published over the past 30 days
Neutral
PRNewsWire
2 weeks ago
Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
LOS ANGELES , Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19 th in Boston, MA. For more information: https://phagefuturesusa.com/events/phage-futures-2024 About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
Negative
Zacks Investment Research
3 weeks ago
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.31 per share a year ago.
Neutral
PRNewsWire
3 weeks ago
Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update
LOS ANGELES , Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2024, and provided a corporate update. Third Quarter 2024 and Recent Developments: Completed enrollment of the Phase 2 study ("Tailwind") of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis ("NCFB") and chronic pulmonary Pseudomonas aeruginosa ("P.
Neutral
PRNewsWire
3 weeks ago
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia
Topline data anticipated in Q1 2025 to support potential initiation of a pivotal bacteremia efficacy trial in 2025 LOS ANGELES , Nov. 12, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has achieved full enrollment (n=50) of its Phase 1b/2a diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia.
Neutral
PRNewsWire
1 month ago
Armata Pharmaceuticals Announces Structural Biology Publication
Publication describes the structure of phage Pa193, a top candidate for inclusion into Armata's multi-phage anti-Pseudomonas clinical products LOS ANGELES , Oct. 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, published by Nature Portfolio. The publication, titled, "Cryo-EM analysis of Pseudomonas phage Pa193 structural components," describes the structure of phage Pa193.
Positive
Zacks Investment Research
2 months ago
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
3 months ago
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
LOS ANGELES , Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.
Neutral
PRNewsWire
3 months ago
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
LOS ANGELES , Aug. 26, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., MS, Chief Medical Officer, will deliver a poster presentation at the 2024 Military Health System Research Symposium (MHSRS), which is being held August 26-29 in Kissimmee, FL.
Neutral
PRNewsWire
3 months ago
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16 th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller.
Neutral
PRNewsWire
3 months ago
Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update
LOS ANGELES , Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2024, and provided a corporate update. Second Quarter 2024 and Recent Developments: Announced completion of enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P.
Charts implemented using Lightweight Charts™